Literature DB >> 31132740

Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.

Maxime Fouchard1, Helene Jantzem2, Gilles Quere1, Renaud Descourt1, Gilles Robinet1, Pierre-Guillaume Poureau3.   

Abstract

Entities:  

Keywords:  Cholangitis; Immune adverse event; Immunotherapy

Mesh：

Substances：

Year:  2019        PMID： 31132740     DOI： 10.1016/j.ejca.2019.04.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  Hepatobiliary and Pancreatic Adverse Events.

Authors:  Hao Chi Zhang; Lan Sun Wang; Ethan Miller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.

Authors:  Borui Pi; Jin Wang; Yifan Tong; Qiao Yang; Fangfang Lv; Yunsong Yu
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

3.  A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis.

Authors:  Ryunosuke Ooi; Kazunori Tobino; Mitsukuni Sakabe; Takafumi Kawabata; Yuri Hiramatsu; Takuto Sueyasu; Kohei Yoshimine
Journal:  Respir Med Case Rep       Date:  2020-08-25

4.  Pembrolizumab-induced large duct cholangiopathy: Diagnosis and follow.up imaging.

Authors:  A Chatterjee; B K Bivas; A Gehani; S Sen
Journal:  J Postgrad Med       Date:  2021 Jan-Mar       Impact factor: 1.476
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.